CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Elite Pharmaceuticals Names Aqeel Fatmi, John LaRocca to Board

By Public Technologies
  • Elite Pharmaceuticals elected Aqeel A. Fatmi and John W. LaRocca to its board on October 28, 2026.
  • The appointments expanded the board from four to six directors.
  • Fatmi previously served as chief scientific officer of Patheon and Banner Life Sciences from 2013 to 2016.
  • LaRocca served as Y-mAbs Therapeutics' senior vice president, general counsel and corporate secretary from January 2024 to October 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611030730NEWSFILECNPR____20261103_322245_1) on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk